Terms: = Lung cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
4373 results:
1. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-pd-1 immunotherapy.
Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
[TBL] [Abstract] [Full Text] [Related]
2. Local therapy combined with anti-pd-1 immunotherapy for advanced lung adenocarcinoma: A case report.
Wu N; Yang X; Zhai Y; Lu W
J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
[TBL] [Abstract] [Full Text] [Related]
3. Outcomes, responses, and prognostic analyses of intrathecal combined treatment for leptomeningeal metastasis from lung adenocarcinoma.
Huang S; Kang X; Wang C; Zhang W; Jiang J; Kang Z; Yang S; Chen J; Chen F; Li W
J Cancer Res Ther; 2024 Apr; 20(2):658-664. PubMed ID: 38687937
[TBL] [Abstract] [Full Text] [Related]
4. Prediction of Responsiveness to PD-L1/pd-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract] [Full Text] [Related]
5. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive lung cancer.
Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
[TBL] [Abstract] [Full Text] [Related]
6. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell lung cancer Treated with pd-1/PD-L1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
7. Evolving insights into the improvement of adoptive T-cell immunotherapy through pd-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract] [Full Text] [Related]
8. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
9. Peripheral CD4
Yang X; Li Q; Zeng T
Front Immunol; 2024; 15():1364507. PubMed ID: 38650951
[TBL] [Abstract] [Full Text] [Related]
10. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-pd-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
11. Association of metabolomics with pd-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
[TBL] [Abstract] [Full Text] [Related]
12. A retrospective study of combination therapy with glucocorticoids and pirfenidone for pd-1 inhibitor-related immune pneumonitis.
Li Y; Huang H; Ye X; Zeng B; Huang F; Chen L
Medicine (Baltimore); 2024 Apr; 103(16):e37808. PubMed ID: 38640289
[TBL] [Abstract] [Full Text] [Related]
13. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract] [Full Text] [Related]
14. The activity and immune dynamics of pd-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.
Cheng B; Li C; Li J; Gong L; Liang P; Chen Y; Zhan S; Xiong S; Zhong R; Liang H; Feng Y; Wang R; Wang H; Zheng H; Liu J; Zhou C; Shao W; Qiu Y; Sun J; Xie Z; Liang Z; Yang C; Cai X; Su C; Wang W; He J; Liang W
Signal Transduct Target Ther; 2024 Apr; 9(1):93. PubMed ID: 38637495
[TBL] [Abstract] [Full Text] [Related]
15. Tetracyclines enhance antitumor T-cell immunity via the Zap70 signaling pathway.
Tone M; Iwahori K; Hirata M; Ueyama A; Tani A; Haruta JI; Takeda Y; Shintani Y; Kumanogoh A; Wada H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38621815
[TBL] [Abstract] [Full Text] [Related]
16. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract] [Full Text] [Related]
17. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell lung cancer Treated with pd-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
18. Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.
Yanagihara T; Hata K; Matsubara K; Kunimura K; Suzuki K; Tsubouchi K; Ikegame S; Baba Y; Fukui Y; Okamoto I
Elife; 2024 Apr; 12():. PubMed ID: 38607373
[TBL] [Abstract] [Full Text] [Related]
19. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-pd-1 efficacy in complementary TNBC models.
Salembier R; De Haes C; Bellemans J; Demeyere K; Van Den Broeck W; Sanders NN; Van Laere S; Lyons TR; Meyer E; Steenbrugge J
Breast Cancer Res; 2024 Apr; 26(1):63. PubMed ID: 38605414
[TBL] [Abstract] [Full Text] [Related]
20. Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-pd-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.
Zhang Y; Chen Z; Liu Y; Han L; Jiang W; Wang Q; Shi J; Lu L; Li J; Zhang M; Huang Y; Yang Y; Hou X; Zhang L; Li J; Fang W; Chen G
Cancer Med; 2024 Apr; 13(7):e7175. PubMed ID: 38597130
[TBL] [Abstract] [Full Text] [Related]
[Next]